These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 33642489)
1. Multiple-line Chemotherapy for a Patient with Unresectable Mucinous Cystic Neoplasm of the Pancreas. Miwa H; Sugimori K; Ishii T; Funaoka A; Tsuchiya H; Suzuki Y; Sugimori M; Nishimura M; Tozuka Y; Komiyama S; Sato T; Kaneko T; Numata K; Maeda S Intern Med; 2021 Aug; 60(16):2607-2612. PubMed ID: 33642489 [TBL] [Abstract][Full Text] [Related]
2. Adjuvant Gemcitabine and Nab-Paclitaxel Misses the Target in Pancreas Adenocarcinoma: Or Did an Effective Therapy Fall to the Definition of Recurrence? Manji GA J Clin Oncol; 2023 Apr; 41(11):1972-1975. PubMed ID: 36854094 [No Abstract] [Full Text] [Related]
3. [A Case of Unresectable Pancreatic Cancer with Massive Cancerous Ascites Responsive to KM-CART]. Shirakawa K; Hirahara S; Kubota H; Kuhara Y; Toyota K; Yano R; Kobayashi H; Hashimoto Y; Yokoyama Y; Sakashita Y; Miyamoto K Gan To Kagaku Ryoho; 2021 Jan; 48(1):81-83. PubMed ID: 33468729 [TBL] [Abstract][Full Text] [Related]
4. The winning formulation: the development of paclitaxel in pancreatic cancer. Ma WW; Hidalgo M Clin Cancer Res; 2013 Oct; 19(20):5572-9. PubMed ID: 23918602 [TBL] [Abstract][Full Text] [Related]
5. Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer. Von Hoff DD; Goldstein D; Renschler MF N Engl J Med; 2014 Jan; 370(5):479-80. PubMed ID: 24476438 [No Abstract] [Full Text] [Related]
6. Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer. Saltz LB; Bach PB N Engl J Med; 2014 Jan; 370(5):478. PubMed ID: 24476439 [No Abstract] [Full Text] [Related]
7. Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer. Sahoo RK; Kumar L N Engl J Med; 2014 Jan; 370(5):478-9. PubMed ID: 24476440 [No Abstract] [Full Text] [Related]
8. [Long-Term Survival following Multidisciplinary Therapy for Unresectable Pancreatic Body Cancer]. Mineta S; Okada T; Sanuki F; Iwamoto R; Kitagawa S; Kinoshita S; Ueno M; Kubota H; Tanaka H; Higashida M; Ito Y; Endo S; Yoshimatsu K; Fujiwara Y; Ueno T Gan To Kagaku Ryoho; 2022 Dec; 49(13):1814-1816. PubMed ID: 36733008 [TBL] [Abstract][Full Text] [Related]
9. Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma. Hegewisch-Becker S; Aldaoud A; Wolf T; Krammer-Steiner B; Linde H; Scheiner-Sparna R; Hamm D; Jänicke M; Marschner N; Int J Cancer; 2019 Mar; 144(5):981-990. PubMed ID: 30006989 [TBL] [Abstract][Full Text] [Related]
10. Advancements in the management of pancreatic cancer: 2013. Saif MW JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549 [TBL] [Abstract][Full Text] [Related]
11. Conversion Surgery for Metastatic Pancreatic Mucinous Carcinoma Responsive to Systemic Chemotherapy with Modified FOLFIRINOX: A Case Report. Yokoyama T; Makino H; Hirakata A; Ueda J; Takata H; Okusa M; Kawashima M; Tsujino T; Hosone M; Matsushita A; Nakamura Y; Yoshida H J Nippon Med Sch; 2019 Dec; 86(5):284-290. PubMed ID: 31105119 [TBL] [Abstract][Full Text] [Related]
12. New therapeutic strategies in the second line setting of advanced or metastatic pancreatic adenocarcinoma. Ramfidis VS; Syrigos KN; Saif MW JOP; 2013 Jul; 14(4):344-6. PubMed ID: 23846924 [TBL] [Abstract][Full Text] [Related]
13. Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients. Yang SH; Guo JC; Hsu C; Kuo SH; Tien YW; Cheng AL; Yeh KH J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):97-105. PubMed ID: 30852003 [TBL] [Abstract][Full Text] [Related]
14. The prognostic impact of tumour location and first-line chemotherapy regimen in locally advanced pancreatic cancer. Takeda T; Sasaki T; Mie T; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Sasahira N Jpn J Clin Oncol; 2021 Apr; 51(5):728-736. PubMed ID: 33611490 [TBL] [Abstract][Full Text] [Related]
15. [A Case of Surgical Resection of Anaplastic Carcinoma of the Pancreas(Pleomorphic Cell Type)with Poor Response to Neoadjuvant Chemotherapy]. Naruse K; Maruyama T; Aono T; Okada T; Suzuki S; Kaneko K; Sato T; Muto I; Hasegawa M; Ichikawa H; Takizawa K; Nakano M; Shimada Y; Sakata J; Wakai T Gan To Kagaku Ryoho; 2021 Dec; 48(13):1601-1603. PubMed ID: 35046269 [TBL] [Abstract][Full Text] [Related]
16. A case of pancreatic mucinous cystadenocarcinoma with malignant ascites without recurrence for more than 8 years after surgery. Tezuka S; Ueno M; Kobayashi S; Fukushima T; Nasu R; Washimi K; Yamamoto N; Morinaga S; Morimoto M; Maeda S Clin J Gastroenterol; 2022 Aug; 15(4):834-839. PubMed ID: 35546381 [TBL] [Abstract][Full Text] [Related]
17. Pancreatic cancer: standing on the shoulders of mice, making an iMPACT on pancreatic cancer. Villanueva MT Nat Rev Clin Oncol; 2013 Dec; 10(12):665. PubMed ID: 24189469 [No Abstract] [Full Text] [Related]
18. New option for the initial management of metastatic pancreatic cancer? Abbruzzese JL; Hess KR J Clin Oncol; 2014 Aug; 32(23):2405-7. PubMed ID: 24982449 [No Abstract] [Full Text] [Related]
19. Dramatic Response to Carboplatin Plus Paclitaxel in Pancreatic Mucinous Cystadenocarcinoma with Liver Metastasis. Oda N; Tabata M; Uno M; Umeda Y; Kato H; Kubo T; Senoo S; Yagi T; Fujiwara T; Maeda Y; Kiura K Intern Med; 2021 Sep; 60(18):2967-2971. PubMed ID: 33814494 [TBL] [Abstract][Full Text] [Related]
20. Delta HU is a potential marker to predict chemotherapy response for unresectable pancreatic ductal adenocarcinoma. Zhou Y; Gao S; Zhou B; Yuan S; Ren H; Wang Y; Guo X; Ren J; Chen Z; Hao J Pancreatology; 2021 Jun; 21(4):763-770. PubMed ID: 33712388 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]